Federal Courts Prepare to Hear Legal Challenges to DEA Schedule III Cannabis Rule

Consolidated Cases Advance After Months of Procedural Maneuvering

Seven separate petitions for review filed between October 2025 and January 2026 have been consolidated into two lead cases. The U.S. Court of Appeals for the D.C. Circuit is handling petitions filed by Florida, Texas, and Nebraska attorneys general, while the Fifth Circuit consolidated challenges brought by Louisiana and Mississippi. According to docket entries filed July 28, 2026, both circuits set identical briefing schedules. Opening briefs from petitioners are due September 15. Government responses follow October 31.

The D.C. Circuit case, captioned State of Florida v. DEA, Docket No. 25-1198, names DEA Administrator Anne Milgram and Attorney General Merrick Garland as respondents. The Fifth Circuit matter, State of Louisiana v. United States, No. 26-60042, raises identical Administrative Procedure Act claims but adds a separate Tenth Amendment challenge to federal preemption of state cannabis prohibitions.

Industry intervenors—including Curaleaf Holdings, Green Thumb Industries, and Trulieve Cannabis—filed notices of intervention in both circuits on June 10, 2026. Those filings preserve the MSOs' ability to defend the rescheduling rule even if the Justice Department settles or declines to mount a vigorous defense.

Core Legal Questions Target DEA's Statutory Authority

Petitioners say the DEA lacked authority to reschedule cannabis to Schedule III without removing it from the Controlled Substances Act entirely. The opening brief preview filed by Florida Attorney General Ashley Moody on July 15 contends that the eight-factor analysis required under 21 U.S.C. § 811(c) compels either Schedule I retention or complete descheduling, with no middle ground. Moody's office cited the 1970 legislative history of the CSA, which classified cannabis alongside heroin based on abuse potential, and said the 2023 Health and Human Services recommendation to reschedule contradicted decades of federal findings.

A second claim says the DEA violated the Administrative Procedure Act's notice-and-comment requirements by finalizing the Schedule III rule on August 30, 2025, without adequately responding to the 43,000 public comments submitted during the 60-day comment period. According to the petition, the DEA's 12-page response to comments failed to address substantive objections raised by the American Medical Association and the National Institute on Drug Abuse regarding cannabis's accepted medical use standard under Schedule III.

The DEA's final rule rests on a regulatory fiction: that a drug illegal under state and federal law for fifty years suddenly meets the "currently accepted medical use" threshold without a single FDA-approved application.

Timing and Briefing Schedule Point to Spring 2027 Oral Arguments

Both circuits have scheduled oral arguments for the April 2027 term, with decisions expected by summer 2027. The D.C. Circuit assigned the case to a three-judge panel on July 22: Judges Patricia Millett, Justin Walker, and Florence Pan. The Fifth Circuit hasn't yet disclosed its panel assignment. Amicus briefs from trade groups, medical associations, and criminal-justice reform organizations are due by November 15, 2026.

On July 29, the National Organization for the Reform of Marijuana Laws and the Drug Policy Alliance filed a joint motion seeking leave to participate as amici curiae in support of the government. NORML's motion says rescheduling, while insufficient, represents the maximum relief available under the CSA's existing framework and that vacatur of the rule would harm patients in 38 medical-cannabis states.

Industry Exposure: $4.2 Billion in Tax Savings Hinge on Rule's Survival

Cannabis operators booked an estimated $4.2 billion in cumulative tax savings for fiscal 2026 based on the assumption that Schedule III status eliminates IRC 280E disallowance of business deductions. Curaleaf's Q2 2026 10-Q, filed July 15, disclosed a $340 million deferred tax asset tied to the rescheduling rule's effective date of September 1, 2025. If a court vacates the rule, operators face retroactive 280E liability and potential amended-return penalties.

The math is brutal.

Trulieve Cannabis CEO Kim Rivers said in an August 1 earnings call that the company has set aside $78 million in escrow to cover potential tax clawbacks if the litigation results in a full or partial vacatur. Green Thumb Industries disclosed a similar $52 million reserve in its July 28 10-Q. Neither company has suspended its Schedule III-based tax planning, but both noted the litigation as a material risk factor.

State-Level Preemption Claims Add Constitutional Dimension

The Fifth Circuit case includes a Tenth Amendment claim absent from the D.C. Circuit litigation. Louisiana Attorney General Liz Murrill's opening brief preview, filed July 18, says the CSA's Schedule III classification unconstitutionally commandeers state enforcement resources by forcing states to choose between maintaining their own cannabis prohibitions or ceding regulatory authority to a federal framework that permits medical use. Her brief cites Murphy v. NCAA, 138 S. Ct. 1461 (2018), which struck down a federal sports-betting prohibition on anti-commandeering grounds.

The Justice Department hasn't yet filed a substantive response, but a July 25 status report indicated DOJ will argue that the CSA's cooperative-federalism structure—allowing states to maintain stricter controls—moots any Tenth Amendment challenge. That argument mirrors the government's successful defense in Gonzales v. Raich, 545 U.S. 1 (2005), which upheld federal cannabis prohibition under the Commerce Clause even in medical-use states.

What Happens Next

Briefing closes in both circuits by year-end 2026. Oral arguments are set for April 2027. Decisions will likely land by June or July. A ruling that vacates the Schedule III rule would immediately reinstate Schedule I status and trigger 280E tax liability for all operators. A ruling that remands the rule for additional notice-and-comment would preserve Schedule III status pending a revised final rule, but would extend uncertainty into 2028.

We'll be watching the September 15 brief filings for early signals on how aggressively DOJ defends the rule and whether industry intervenors break with the government's legal strategy.

For full background on the rescheduling process and prior litigation, see the CannIntel topic hub on Schedule III legal challenges.